Warning letter · FDA Warning Letters

Quality Supplement Manufacturing, Inc.: FDA Warning Letter 637182 (Dec 13, 2022)

Agency action: Dec 13, 2022Record ID: fda_warning_-3c47b43a95431bde
View official source ↗

What happened

Original notice title

Quality Supplement Manufacturing, Inc. MARCS-CMS 637182, December 13, 2022

From the archived source record

Based on inspectional findings and a review of your product labels, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. We have reviewed that document and our comments are listed following each of the significant violations. Adulterated Dietary Supplements The inspection of your facility revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Based on the inspection, we determined that your products, including your (b)(4) , and (b)(4) products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. The significant violations documented during the inspection include, but are not limited to the following: 1. Misbranded Dietary Supplements In addition, even if your (b)(4) product was not an unapproved new and misbranded drug, this product and others would be misbranded under section 403 of the Act because it does not comply with the labeling requirements for dietary supplements. Your (b)(4) and (b)(4) dietary supplement products are misbranded under section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling for your products does not comply with the labeling requirements for dietary supplements in 21 CFR 101.36. Your (b)(4) product is misbranded within the meaning of section 403(w)(2) of the Act [21 U.S.C. § 343(w)(2)], in that the finished product labels fail to declare the major food allergen, shrimp and crab, as required by section 403(w)(1) of the Act.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
99a9aede0177

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
tablet won’t hit the weight so running (b)(4); [the] Quality Department will be signing off on all finished product test results; flavorless coating (Yellow 5, Red 40, Blue 1)
Company
Quality Supplement Manufacturing, Inc.
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.